Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Malaria Pipeline Drugs Market Overview
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children.
The Malaria pipeline drugs market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.
Malaria Pipeline Products Market Segmentation by Targets
The key targets in the Malaria pipeline drugs market are Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and others.
Malaria Pipeline drugs Market Analysis by Targets
For more target insights into the Malaria pipeline products market, download a free report sample
Malaria Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Malaria pipeline drugs market are P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and others.
Malaria Pipeline drugs Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Malaria pipeline products market, download a free report sample
Malaria Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Malaria pipeline drugs market are oral, intramuscular, intravenous, subcutaneous, parenteral, intradermal, inhalational, nasal, and transdermal.
Malaria Pipeline drugs Market Analysis by Routes of Administration
For more routes of administration insights into the Malaria pipeline products market, download a free report sample
Malaria Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Malaria pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, monoclonal antibody, live attenuated vaccine, mRNA vaccine, DNA vaccine, antisense oligonucleotide, antisense RNAi oligonucleotide, and others.
Malaria Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Malaria pipeline products market, download a free report sample
Competitive Landscape
Some of the leading players in the Malaria pipeline products market are Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA.
Malaria Pipeline Products Market Analysis by Players
To know more about the leading players in the Malaria pipeline products market, download a free report sample
Malaria Pipeline Products Market Report Overview
Key Targets | Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and Others |
Key Mechanisms of Action | P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and Others |
Key Routes of Administration | Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Intradermal, Inhalational, Nasal, and Transdermal |
Key Molecule Type | Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Vaccine, Monoclonal Antibody, Live Attenuated Vaccine, mRNA Vaccine, DNA Vaccine, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, and Others |
Leading Players | Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
AchilleS Vaccines Srl
Alfasigma SpA
AliquantumRx Inc
Allergy Therapeutics Plc
Altimmune Inc
Artemis Therapeutics Inc
Artificial Cell Technologies Inc
Atomwise Inc
AUM LifeTech Inc
Avalia Immunotherapies Ltd
Bharat Biotech Ltd
BioNTech SE
Blue Water Vaccines Inc
Brain-Gen LLC
Bristol-Myers Squibb Co
Carna Biosciences Inc
Cascade Therapeutics Inc
Cellics Therapeutics Inc
Cesa Alliance SA
Cilian AG
Collaborations Pharmaceuticals Inc
Crystec Ltd
Curevac NV
Curia Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
ElSohly Laboratories Inc
EpicentRx Inc
EpiVax Inc
eTheRNA Immunotherapies NV
Evotec SE
Expres2ion Biotechnologies ApS
Exscientia Plc
GeoVax Labs Inc
GSK plc
Hawaii Biotech Inc
Ibex Biosciences LLC
Ichor Medical Systems Inc
IGM Biosciences Inc
Immune Modulation Inc
Imutex Ltd
IMV Inc
Indoco Remedies Ltd
Innovex Therapeutics SL
IPCA Laboratories Ltd
Jacobus Pharmaceutical Co Inc
Johnson & Johnson
Kainomyx Inc
Kymab Ltd
Luckwel Pharmaceuticals Inc
Lumen Bioscience Inc
Lyndra Therapeutics Inc.
MedinCell SA
MediSynergics LLC
MegaNano BioTech Inc
Merck & Co Inc
Merck KGaA
Microbiotix Inc
Mitsubishi Tanabe Pharma Corp
Modus Therapeutics AB
Mycosynthetix Inc
Mymetics Corp
Nobelpharma Co Ltd
Novartis AG
Ocean Biomedical Inc
Osivax SAS
Otsuka Pharmaceutical Co Ltd
Pacific Meniuoke Biopharmaceutical Company
Pfizer Inc
PGTx Ltd
Protein Potential LLC
Replikins Ltd
Rodos BioTarget GmbH
Sanaria Inc
Sanofi
Serum Institute of India Pvt Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Sumaya Biotech GmbH & Co KG
Sumitomo Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Tandem Nano Ltd
Tarsus Pharmaceuticals Inc
Theravectys SA
UCB SA
Uvax Bio LLC
Vac4All SAS
VicuTec Biologicals GmbH
VLP Biotech Inc
VLP Therapeutics LLC
Zydus Lifesciences Ltd
Table of Contents
Frequently asked questions
-
What are the key targets in the Malaria pipeline products market?
The key targets in the Malaria pipeline products market are Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum 25 kDa Ookinete Surface Antigen, Plasmodium falciparum Merozoite Surface Protein 1, P Type ATPase4, Beta Hematin, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Heme Polymerase, Plasmodium falciparum Apical Membrane Antigen 1, Plasmodium falciparum Gametocyte Surface Protein P45/48, Plasmodium falciparum Reticulocyte Binding Protein Homologue 5, and others.
-
What are the key mechanisms of action in the Malaria pipeline products market?
The key mechanisms of action in the Malaria pipeline products market are P Type ATPase4 Inhibitor, Plasmodium falciparum Circumsporozoite Protein Inhibitor, Beta Hematin Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Heme Polymerase Inhibitor, 16S Ribosomal RNA Inhibitor, Cytochrome bc1 Complex Inhibitor, Dihydrofolate Reductase Inhibitor, DNA Inhibitor, Histone Lysine N Methyltransferase EHMT2 Inhibitor, and others.
-
What are the key routes of administration in the Malaria pipeline products market?
The key routes of administration in the Malaria pipeline products market are oral, intramuscular, intravenous, subcutaneous, parenteral, intradermal, inhalational, nasal, and transdermal.
-
What are the key molecule types in the Malaria pipeline products market?
The key molecule types in the Malaria pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, monoclonal antibody, live attenuated vaccine, mRNA vaccine, DNA vaccine, antisense oligonucleotide, antisense RNAi oligonucleotide, and others.
-
Who are the leading players in the Malaria pipeline products market?
Some of the leading players in the Malaria pipeline products market are Eisai Co Ltd, GSK plc, Novartis AG, Sanaria Inc, Vac4All SAS, Zydus Lifesciences Ltd, Expres2ion Biotechnologies ApS, Ocean Biomedical Inc, Sanofi, and Alfasigma SpA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports

